Lesley Scott to Mycobacterium tuberculosis
This is a "connection" page, showing publications Lesley Scott has written about Mycobacterium tuberculosis.
Connection Strength
4,779
-
Rifampicin-resistant TB: discordance between Xpert® MTB/RIF and MTBDRplus results. Int J Tuberc Lung Dis. 2021 10 01; 25(10):832-838.
Score: 0,585
-
Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting. J Mol Diagn. 2020 10; 22(10):1225-1237.
Score: 0,540
-
Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018 12; 56(12).
Score: 0,480
-
Diagnosis of opportunistic infections: HIV co-infections - tuberculosis. Curr Opin HIV AIDS. 2017 03; 12(2):129-138.
Score: 0,426
-
Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011 Jul; 8(7):e1001061.
Score: 0,289
-
Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance. J Mol Diagn. 2024 Aug; 26(8):708-718.
Score: 0,176
-
Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization-Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis?and Resistance to Rifampicin and Isoniazid. J Mol Diagn. 2023 01; 25(1):46-56.
Score: 0,157
-
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2022 02; 22(2):242-249.
Score: 0,146
-
Diagnostic performance of the Abbott RealTime MTB assay for tuberculosis diagnosis in people living with HIV. Sci Rep. 2021 09 29; 11(1):19271.
Score: 0,146
-
Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid. J Clin Microbiol. 2021 02 18; 59(3).
Score: 0,140
-
Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa. Int J Tuberc Lung Dis. 2021 02 01; 25(2):134-141.
Score: 0,140
-
Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact. J Antimicrob Chemother. 2020 05 01; 75(5):1123-1129.
Score: 0,133
-
Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. J Infect Dis. 2019 10 08; 220(220 Suppl 3):S99-S107.
Score: 0,128
-
The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. J Antimicrob Chemother. 2018 10 01; 73(10):2667-2674.
Score: 0,119
-
Molecular Detection of Mycobacterium tuberculosis from Stools in Young Children by Use of a Novel Centrifugation-Free Processing Method. J Clin Microbiol. 2018 09; 56(9).
Score: 0,118
-
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018 01; 18(1):76-84.
Score: 0,112
-
Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study. Clin Infect Dis. 2017 Jun 01; 64(11):1502-1508.
Score: 0,108
-
Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control. Microbiol Spectr. 2017 01; 5(1).
Score: 0,105
-
The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF. Int J Tuberc Lung Dis. 2015 Jul; 19(7):811-6.
Score: 0,095
-
Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs. 2015 Jan; 75(1):91-100.
Score: 0,092
-
Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014 Jun 01; 189(11):1426-34.
Score: 0,088
-
Successes, challenges and lessons from a novel deployment of Xpert(®) MTB/RIF at a major South African public event [Short Communication]. Int J Tuberc Lung Dis. 2014 Apr; 18(4):438-40.
Score: 0,087
-
Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
Score: 0,082
-
Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Int J Tuberc Lung Dis. 2013 Mar; 17(3):368-72.
Score: 0,081
-
Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012 Sep 07; 102(10):805-7.
Score: 0,078
-
False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis. 2012 Feb; 16(2):206-8.
Score: 0,075
-
A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries. BMC Infect Dis. 2016 06 10; 16:269.
Score: 0,025
-
Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010 Oct; 10(7):937-46.
Score: 0,017
-
Tuberculosis in east timorese refugees: implications for health care needs in East Timor. Int J Tuberc Lung Dis. 2002 Nov; 6(11):980-7.
Score: 0,010